Fabry disease

Active Ingredient: Pegunigalsidase alfa

Indication for Pegunigalsidase alfa

Population group: only adults (18 years old or older)
Therapeutic intent: Curative procedure

Pegunigalsidase alfa is indicated for long-term enzyme replacement therapy in adult patients with a confirmed diagnosis of Fabry disease (deficiency of alpha-galactosidase).

For this indication, competent medicine agencies globally authorize below treatments:

1 mg/kg of body weight once every two weeks

For:

Dosage regimens

Intravenous, 1 milligrams pegunigalsidase alfa per kilogram of body weight, once every 2 weeks.

Detailed description

The recommended dose of pegunigalsidase alfa is 1 mg/kg of body weight administered once every two weeks.

Patients switching treatment from agalsidase alfa or beta

For the initial 3 months (6 infusions) of treatment with pegunigalsidase alfa, pre-treatment regimen should be preserved with stepwise discontinuation of pre-treatment based on appropriate tolerability of the patients.

Elderly (≥65 years old)

Safety and efficacy of pegunigalsidase alfa in patients older than 65 years have not been evaluated and no alternative dose regimens can be recommended for these patients. Elderly patients may be treated with the same dose as other adult patients.

Dosage considerations

For intravenous infusion use only.

Pegunigalsidase alfa must not be infused in the same intravenous line with other products.

The patient should be observed for infusion-related reactions (IRRs) for two hours after the infusion.

Active ingredient

Pegunigalsidase alfa

The active substance of pegunigalsidase alfa is pegunigalsidase alfa. Pegunigalsidase alfa is a pegylated recombinant form of human α-galactosidase-A. The amino acid sequence of the recombinant form is similar to the naturally occurring human enzyme. Pegunigalsidase alfa supplements or replaces α-galactosidase-A, reducing the amount of accumulation of globotriaosylceramide (Gb3) and globotriaosylsphingosine (Lyso-Gb3).

Read more about Pegunigalsidase alfa

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.